跳至主要内容
临床试验/EUCTR2010-019962-10-FR
EUCTR2010-019962-10-FR进行中(未招募)不适用

AN OPEN-LABEL, SINGLE ARM, MONOCENTRIC, PHASE I/II CLINICAL STUDY OF INTRACEREBRAL ADMINISTRATION OF ADENO-ASSOCIATED VIRAL VECTORS SEROTYPE 10 CARRYING THE HUMAN SGSH AND SUMF1 cDNAS FOR THE TREATMENT OF SANFILIPPO TYPE A SYNDROME - Intracerebral Gene therapy for Sanfilippo type A syndrome

SANFILIPPO Therapeutics SAS0 个研究点目标入组 4 人开始时间: 2010年11月19日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
4

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age: 18 (eighteen) months to end of 6 (six) years
  • Onset of clinical manifestations related to MPSIIIA during the first 5 years of life
  • SGSH activity in peripheral blood cell and/or cultured fibroblast extracts of less than 10% of controls.
  • Patient affiliated to the social security
  • Family understanding the procedure and the informed consent
  • Signed informed consent
  • Vital laboratory parameters within normal range
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Presence of brain atrophy on pre-inclusion MRI judged on a cortico-dural distance of more than 1cm
  • No independent walking (Ability to walk without help)
  • Any condition that would contraindicate permanently anaesthesia
  • Any other permanent medical condition not related to MPSIIIA
  • Any vaccination 1 month before treatment
  • Receipt of aspirin within one month
  • Any medication aiming at modifying the natural course of MPSIIIA given during the 6 months before vector injection
  • Any condition that would contraindicate treatment with Prograf®, Cellcept® and Solupred®

研究者

相似试验

进行中(未招募)
1 期
Phase I/II study evaluating AUTO4 (an experimental drug derived from the patient's own blood) in patients with T Cell Lymphoma (a type of blood cancer)
EUCTR2017-001965-26-GBAutolus Ltd200
进行中(未招募)
1 期
Phase I/II study evaluating AUTO4 (an experimental drug derived from the patient's own blood) in patients with T Cell Lymphoma (a type of blood cancer)Relapsed or refractory T cell Non-Hodgkin Lymphoma (T-NHL)MedDRA version: 20.0 Level: HLGT Classification code 10025321 Term: Lymphomas non-Hodgkin's T-cell System Organ Class: 10005329 - Blood and lymphatic system disorders
EUCTR2017-001965-26-ESAutolus Ltd200
进行中(未招募)
1 期
A study to assess the detection of the BRAF V600 mutation on cfDNA from plasma in patients with advanced melanomaMedDRA version: 20.0 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864Melanoma
EUCTR2015-001731-20-BEF. Hoffmann-La Roche Ltd208
进行中(未招募)
1 期
A study to assess the detection of the BRAF V600 mutation on cfDNA from plasma in patients with advanced melanomaMelanoma
EUCTR2015-001731-20-PLF. Hoffmann-La Roche Ltd208
进行中(未招募)
1 期
A multicenter prospective study on the cost / benefit / safety of Sofosbuvir administered to patients with chronic hepatitis C virus and Mixed CryoglobulinemiaHCV chronic hepatitis and Mixed CryoglobulinemiaMedDRA version: 17.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: LLTClassification code 10027756Term: Mixed cryoglobulinemiaSystem Organ Class: 100000004866
EUCTR2014-004134-26-ITCentro Masve -Università degli Studi di Firenze-AOUC30